CNOT2 promotes proliferation and angiogenesis via VEGF signaling in MDA-MB-231 breast cancer cells

Sohn, Eun Jung; Jung, Deok‐Beom; Lee, HyoJung; Han, Ihn; Lee, Ji‐Hyun; Kim, Ju‐Ha

doi:10.1016/j.canlet.2017.09.052

Cited by 50 publications

(51 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the function of VEGF-A in cancer is not limited to angiogenesis [21]. VEGF-A also takes important contribution for other aspects of cancer onset and progression, like tumour cell proliferation [27], migration [28] and invasion [29]. Herein, VEGF-A was found to be a target of miR-126.…”

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: The anti-osteosarcoma property of ailanthone through regulation of miR-126/VEGF-A axis

Kong

Ying

Zhang

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Background: Despite the characters of the resistance of tumour of ailanthone (AIL) were found in various tumour cells, its effect on osteosarcoma is still unclear. Herein, we attempted to see the effects of AIL on an osteosarcoma cell line MG63. Methods: MG63 cells were treated by AIL, following which CCK-8 assay, BrdU assay, Transwell assay and Western blot were utilized to detect cell proliferation, migration, invasion and apoptosis. miR-126 expression in osteosarcoma tissues and cell lines was measured by qRT-PCR. Further, the target of miR-126 and the downstream signalling for AIL were studied. Results: Treating MG63 cells with 1.5 lM AIL for 24 h significantly suppressed proliferation, migration, invasion and induced apoptosis. Meanwhile, AIL inhibited PI3K/AKT pathway and up-regulated miR-126 expression. miR-126 of osteosarcoma tissues and cell lines was low expressed, as relative to paracancerous tissues and normal osteoblast. The anti-tumour effects of AIL were attenuated by miR-126 silencing. Further, VEGF-A was a target of miR-126. Conclusions: This study demonstrated that AIL was effective in inhibiting MG63 cells growth, migration and invasion. The anti-tumour properties may be via up-regulating miR-126 and thereby degradation of VEGF-A.

show abstract

Section: Discussionmentioning

confidence: 99%

RETRACTED ARTICLE: The anti-osteosarcoma property of ailanthone through regulation of miR-126/VEGF-A axis

Kong

Ying

Zhang

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…Data from the TCGA Fusion Gene Database showed that the some of the candidate genes form chimeras with a variety of partners in different tumor types, suggesting that they might locate in genomic regions prone to chromosomal rearrangements [46,47] and/or have a role in carcinogenesis. The most frequently altered genes were CPD and CNOT2, whose overexpression was associated with survival, inhibition of apoptosis and angiogenesis in different cancer types [22,[48][49][50][51]. Regarding the other genes that were rarely rearranged across cancer, they might participate to the leukemic phenotype, even though not being the driver of transformation.…”

Section: Discussionmentioning

confidence: 99%

Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia

Padella

Simonetti

Paciello

et al. 2019

Cancers

View full text Add to dashboard Cite

Approximately 18% of acute myeloid leukemia (AML) cases express a fusion transcript. However, few fusions are recurrent across AML and the identification of these rare chimeras is of interest to characterize AML patients. Here, we studied the transcriptome of 8 adult AML patients with poorly described chromosomal translocation(s), with the aim of identifying novel and rare fusion transcripts. We integrated RNA-sequencing data with multiple approaches including computational analysis, Sanger sequencing, fluorescence in situ hybridization and in vitro studies to assess the oncogenic potential of the ZEB2-BCL11B chimera. We detected 7 different fusions with partner genes involving transcription factors (OAZ-MAFK, ZEB2-BCL11B), tumor suppressors (SAV1-GYPB, PUF60-TYW1, CNOT2-WT1) and rearrangements associated with the loss of NF1 (CPD-PXT1, UTP6-CRLF3). Notably, ZEB2-BCL11B rearrangements co-occurred with FLT3 mutations and were associated with a poorly differentiated or mixed phenotype leukemia. Although the fusion alone did not transform murine c-Kit+ bone marrow cells, 45.4% of 14q32 non-rearranged AML cases were also BCL11B-positive, suggesting a more general and complex mechanism of leukemogenesis associated with BCL11B expression. Overall, by combining different approaches, we described rare fusion events contributing to the complexity of AML and we linked the expression of some chimeras to genomic alterations hitting known genes in AML.

show abstract

“…Studies on mRNA‐seq data of thymoma confirm such notion by showing the correlation between the low levels of CNOT2/CNOT9 and the poor survival. However, in studies with other cancer types, CNOT2 was also reported to play roles in promoting tumor progression (Gupta et al , ; Paone et al , ; Sohn et al , ), possibly by downregulation of MHC II expression as evidenced in several cell line and animal models (Rodriguez‐Gil et al , ), therefore undermined immunosurveillance of cancer. Serine hydroxymethyltransferase 1 (SHMT1), a key enzyme catalyzing the folate‐dependent serine/glycine interconversion during cellular metabolism processes, showed an extremely low level of expression in the TSCC (Fig.…”

Section: Discussionmentioning

confidence: 99%

Deciphering tissue‐based proteome signatures revealed novel subtyping and prognostic markers for thymic epithelial tumors

Sun

Zhu

et al. 2020

Molecular Oncology

View full text Add to dashboard Cite

Thymic epithelial tumors (TETs) belong to a group of tumors that rarely occur, but have unresolved mechanisms and heterogeneous clinical behaviors. Current care of TET patients demands biomarkers of high sensitivity and specificity for accurate histological classification and prognosis management. In this study, 134 fresh‐frozen tissue samples (84 tumor, 40 tumor adjacent, and 10 normal thymus) were recruited to generate a quantitative and systematic view of proteomic landscape of TETs. Among them, 90 samples were analyzed by data‐independent acquisition mass spectrometry (DIA‐MS) leading to discovery of novel classifying molecules among different TET subtypes. The correlation between clinical outcome and the identified molecules was probed, and the prioritized proteins of interest were further validated on the remaining samples (n = 44) via parallel reaction monitoring (PRM) as well as immunohistochemical and confocal imaging analysis. In particular, two proteins, the cellular mRNA deadenylase CCR4 (carbon catabolite repressor 4)‐NOT (negative on TATA) complex subunit 2/9 (CNOT2/9) and the serine hydroxymethyltransferase that catalyzes the reversible interconversions of serine and glycine (SHMT1), were found at dramatic low levels in the thymic epithelia of more malignant subtype, thymic squamous cell carcinoma (TSCC). Interestingly, the mRNA levels of these two genes were shown to be closely correlated with prognosis of the TET patients. These results extended the existing human tissue proteome atlas and allowed us to identify several new protein classifiers for TET subtyping. Newly identified subtyping and prognosis markers, CNOT2/9 and SHMT1, will expand current diagnostic arsenal in terms of higher specificity and prognostic insights for TET diagnosis and management.

show abstract

CNOT2 promotes proliferation and angiogenesis via VEGF signaling in MDA-MB-231 breast cancer cells

Cited by 50 publications

References 31 publications

RETRACTED ARTICLE: The anti-osteosarcoma property of ailanthone through regulation of miR-126/VEGF-A axis

RETRACTED ARTICLE: The anti-osteosarcoma property of ailanthone through regulation of miR-126/VEGF-A axis

Novel and Rare Fusion Transcripts Involving Transcription Factors and Tumor Suppressor Genes in Acute Myeloid Leukemia

Deciphering tissue‐based proteome signatures revealed novel subtyping and prognostic markers for thymic epithelial tumors

Contact Info

Product

Resources

About